Compare Stocks: OSRH, ALGS, MDXH, and RADX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALGS Aligos Therapeutics	$6.76 +2.9%	$5.58	$3.98 ▼ $13.69	$43.03M	2.31	158,939 shs	110,130 shs
MDXH MDxHealth	$0.75 -12.2%	$0.48	$0.40 ▼ $5.33	$39.99M	1.42	16.95 million shs	2.62 million shs
OSRH OSR	$0.43 -27.1%	$0.39	$0.25 ▼ $1.24	$11.10M	0.55	702,154 shs	144.66 million shs
RADX Radiopharm Theranostics	$2.62 -1.9%	$3.83	$2.45 ▼ $16.25	$37.01M	1.63	145,789 shs	39,474 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALGS Aligos Therapeutics	-4.64%	-14.12%	+14.46%	+26.83%	-14.68%
MDXH MDxHealth	+5.89%	+88.46%	+102.37%	+1.94%	-69.98%
OSRH OSR	+86.71%	+43.69%	+26.28%	+15.71%	+11.43%
RADX Radiopharm Theranostics	+4.30%	-4.64%	-39.73%	-42.46%	-45.40%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALGS Aligos Therapeutics	$6.76 +2.9%	$5.58	$3.98 ▼ $13.69	$43.03M	2.31	158,939 shs	110,130 shs
MDXH MDxHealth	$0.75 -12.2%	$0.48	$0.40 ▼ $5.33	$39.99M	1.42	16.95 million shs	2.62 million shs
OSRH OSR	$0.43 -27.1%	$0.39	$0.25 ▼ $1.24	$11.10M	0.55	702,154 shs	144.66 million shs
RADX Radiopharm Theranostics	$2.62 -1.9%	$3.83	$2.45 ▼ $16.25	$37.01M	1.63	145,789 shs	39,474 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALGS Aligos Therapeutics	-4.64%	-14.12%	+14.46%	+26.83%	-14.68%
MDXH MDxHealth	+5.89%	+88.46%	+102.37%	+1.94%	-69.98%
OSRH OSR	+86.71%	+43.69%	+26.28%	+15.71%	+11.43%
RADX Radiopharm Theranostics	+4.30%	-4.64%	-39.73%	-42.46%	-45.40%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALGS Aligos Therapeutics	2.86	Moderate Buy	$38.50	469.53% Upside
MDXH MDxHealth	2.40	Hold	$2.83	277.17% Upside
OSRH OSR	1.00	Sell	N/A	N/A
RADX Radiopharm Theranostics	2.33	Hold	$11.00	319.85% Upside

Current Analyst Ratings Breakdown

Latest OSRH, ALGS, MDXH, and RADX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/14/2026	MDXH MDxHealth	Lake Street Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target	Buy	$5.00 ➝ $3.00
8/11/2026	ALGS Aligos Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/10/2026	ALGS Aligos Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
7/28/2026	ALGS Aligos Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/17/2026	RADX Radiopharm Theranostics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/10/2026	ALGS Aligos Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
6/25/2026	ALGS Aligos Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
6/24/2026	OSRH OSR	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
6/4/2026	RADX Radiopharm Theranostics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$6.00
5/29/2026	ALGS Aligos Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
5/28/2026	ALGS Aligos Therapeutics	Lake Street Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$45.00

(Data available from 8/18/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALGS Aligos Therapeutics	$2.19M	19.26	N/A	N/A	$8.67 per share	0.78
MDXH MDxHealth	$107.88M	0.34	N/A	N/A	($0.24) per share	-3.13
OSRH OSR	$2.91M	5.19	N/A	N/A	$4.95 per share	0.09
RADX Radiopharm Theranostics	$2.35M	16.12	N/A	N/A	$3.52 per share	0.74

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALGS Aligos Therapeutics	-$24.19M	-$7.30	N/A	N/A	N/A	-241.01%	-160.72%	-92.30%	11/5/2026 (Estimated)
MDXH MDxHealth	-$33.52M	-$0.72	N/A	N/A	N/A	-33.46%	N/A	-24.25%	N/A
OSRH OSR	-$27.06M	-$0.37	N/A	N/A	N/A	-593.15%	-8.28%	-6.18%	N/A
RADX Radiopharm Theranostics	-$24.83M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Latest OSRH, ALGS, MDXH, and RADX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2026	Q2 2026	OSRH OSR	N/A	-$0.02	N/A	-$0.02	N/A	$0.32 million
8/13/2026	Q2 2026	MDXH MDxHealth	-$0.1934	-$0.18	+$0.0134	-$0.22	$26.14 million	$27.21 million
8/6/2026	Q2 2026	ALGS Aligos Therapeutics	-$1.09	-$0.14	+$0.95	-$0.14	$24.68 million	$27.78 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALGS Aligos Therapeutics	N/A	N/A	N/A	N/A	N/A
MDXH MDxHealth	N/A	N/A	N/A	N/A	N/A
OSRH OSR	N/A	N/A	N/A	N/A	N/A
RADX Radiopharm Theranostics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALGS Aligos Therapeutics	N/A	2.19	2.19
MDXH MDxHealth	N/A	1.15	0.98
OSRH OSR	N/A	0.16	0.14
RADX Radiopharm Theranostics	N/A	3.01	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALGS Aligos Therapeutics	60.43%
MDXH MDxHealth	N/A
OSRH OSR	55.30%
RADX Radiopharm Theranostics	N/A

Insider Ownership

Company	Insider Ownership
ALGS Aligos Therapeutics	7.80%
MDXH MDxHealth	1.70%
OSRH OSR	36.90%
RADX Radiopharm Theranostics	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALGS Aligos Therapeutics	90	6.24 million	5.76 million	No Data
MDXH MDxHealth	300	49.50 million	48.66 million	Not Optionable
OSRH OSR	N/A	35.12 million	22.16 million	N/A
RADX Radiopharm Theranostics	N/A	14.46 million	N/A	N/A

OSRH, ALGS, MDXH, and RADX Headlines

Recent News About These Companies

Radiopharm Theranostics To Meet with U.S. FDA to Align on Pivotal Phase 3 Trial Design for RAD 101 in Diagnosis of Brain Metastases

August 17 at 9:40 AM | finance.yahoo.com

RADX: RAD101 Topline & FY:26 Cash Flows

August 3, 2026 | finance.yahoo.com

Radiopharm Dips on Securities Pact

July 25, 2026 | baystreet.ca

Radiopharm Theranostics Announces Concurrent US$4.1 Million Registered Direct Offering and Up To Additional A$12.7 (US$8.9) Million Australian Placement and Share Purchase Plan

July 24, 2026 | globenewswire.com

Radiopharm Highlights Data Release

July 23, 2026 | baystreet.ca

Radiopharm Theranostics Achieves Confirmed Durable Partial Response in Ongoing Phase 1 Trial of RAD204 in Patients with Advanced Solid Tumors Post-Immunotherapy

July 22, 2026 | globenewswire.com

Radiopharm Theranostics Announces Positive Phase 2b Trial Results of RAD 101 for Diagnosis of Brain Metastases

July 22, 2026 | globenewswire.com

Radiopharm Theranostics Ltd ADR RADX

July 16, 2026 | morningstar.comM

Radiopharm Theranostics Limited Sponsored ADR

May 14, 2026 | cnn.com

RADX: Fiscal 3Q:26 Cash Flow Report

May 13, 2026 | finance.yahoo.com

Radiopharm Theranostics Ltd. ADR

May 13, 2026 | barrons.com

Radiopharm Theranostics ADR (RADX): Inside the Clinical Programs

April 28, 2026 | insidermonkey.com

Radiopharm Theranostics Reports Business Update

April 23, 2026 | globenewswire.com

Radiopharm Theranostics Presents Initial Findings from Phase 1 First-in-Human HEAT Clinical Trial for 177Lu-RAD202 in HER2+ Solid Tumors at American Association for Cancer ...

April 20, 2026 | finance.yahoo.com

Radiopharm Theranostics Completes Enrollment in U.S. Phase 2b Imaging Trial of RAD 101 for Diagnosis of Brain Metastases

April 16, 2026 | markets.businessinsider.com

Radiopharm Theranostics Limited - Depositary Receipt (RADX) price target increased by 752.98% to 39.26

April 16, 2026 | msn.com

Radiopharm Theranostics Limited - Depositary Receipt (RADX) price target decreased by 11.04% to 4.60

April 9, 2026 | msn.com

Radiopharm Theranostics Advances to Cohort 3 in 177Lu-RAD202 Phase 1 Dose Escalating Clinical Trial

April 8, 2026 | markets.businessinsider.com

Radiopharm Theranostics and Siemens Healthineers Sign Clinical Supply Agreement for RAD101 in the U.S.

April 7, 2026 | globenewswire.com

RADX: RAD 101 Phase IIb Interim Analysis

April 6, 2026 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

OSRH, ALGS, MDXH, and RADX Company Descriptions

Aligos Therapeutics NASDAQ:ALGS

$6.76 +0.19 (+2.89%)

Closing price 04:00 PM Eastern

Extended Trading

$6.64 -0.12 (-1.78%)

As of 07:30 PM Eastern

Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). The company also develops ALG-000184, a capsid assembly modulator, which is completed Phase 1b clinical trial to treat chronic hepatitis B (CHB); and ALG-125755, a siRNA drug candidate, which is in Phase I clinical trial for the treatment of CHB. In addition, it develops ALG-097558, which is in Phase 2 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH; license agreement with Emory University to provide hepatitis B virus capsid assembly modulator technology; license agreement with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; and research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors. Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

MDxHealth NASDAQ:MDXH

$0.75 -0.10 (-12.20%)

Closing price 04:00 PM Eastern

Extended Trading

$0.74 -0.01 (-0.96%)

As of 07:59 PM Eastern

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its testing solutions includes Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolved mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection. The company offers genomic prostate score which provides personalized genomic insights to both physicians and patients navigating the complexities of prostate cancer diagnosis and treatment. It sells its products through urology sales force, consisting of direct sales representatives, strategic account managers, and regional sales managers. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.

OSR NASDAQ:OSRH

$0.43 -0.16 (-27.12%)

Closing price 04:00 PM Eastern

Extended Trading

$0.35 -0.08 (-17.91%)

As of 07:59 PM Eastern

OSR Holdings leverages its international network of partners in the US, Europe, and South Korea to market and license its pipeline of proprietary platform technologies for broad application to efficient clinical trial programs, with the ultimate goal of addressing unmet medical needs. We partner with biotherapeutics companies with innovative and proprietary drug R&D "platform technologies" versus "assets only" companies, whose commercial viability is heavily dependent on positive results for individual treatment modalities in extremely rigorous and time consuming clinical trials. We focus on value creation through investments and collaborations with US and EU biotech companies, with the strategic goal of expansion into South Korea (specifically) and Asia (generally). OSR Holdings is headquartered in Paju, South Korea.

Radiopharm Theranostics NASDAQ:RADX

$2.62 -0.05 (-1.87%)

Closing price 04:00 PM Eastern

Extended Trading

$2.62 0.00 (-0.19%)

As of 07:34 PM Eastern

Radiopharm Theranostics Ltd. operates as a pre-clinical and clinical research company. It focuses on the development of radiopharmaceutical products for diagnostic and therapeutic uses in areas of high unmet medical need. The company is headquartered Carlton, Australia.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest OSRH, ALGS, MDXH, and RADX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest OSRH, ALGS, MDXH, and RADX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

OSRH, ALGS, MDXH, and RADX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

OSRH, ALGS, MDXH, and RADX Company Descriptions

Aligos Therapeutics NASDAQ:ALGS

MDxHealth NASDAQ:MDXH

OSR NASDAQ:OSRH

Radiopharm Theranostics NASDAQ:RADX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest OSRH, ALGS, MDXH, and RADX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest OSRH, ALGS, MDXH, and RADX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

OSRH, ALGS, MDXH, and RADX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

OSRH, ALGS, MDXH, and RADX Company Descriptions

Aligos Therapeutics NASDAQ:ALGS

MDxHealth NASDAQ:MDXH

OSR NASDAQ:OSRH

Radiopharm Theranostics NASDAQ:RADX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools